Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling

E. Yukawa, H. To, Shigehiro Ohdo, S. Higuchi, T. Aoyama

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effects of drug interaction on phenobarbitone clearance values, using 648 serum levels gathered during the routine clinical care of 349 pediatric and adult epileptic patients (age range, 0.4-33.3 years). Patients received phenobarbitone as monotherapy or in combination with either of the antiepileptic drugs carbamazepine or valproic acid. Results: The final model describing phenobarbitone clearance was CL = 52.3·TBW-0.567. CO, where CL is clearance (ml· kg-1· h-1), TBW is total body weight (kg) and CO is a scaling factor for concomitant medication with a value of 1 for patients on phenobarbitone monotherapy, 46.4(-1/TBW) for those patients receiving concomitant carbamazepine and 0.642 for those patients receiving concomitant valproic acid. Phenobarbitone CL was highest in the very young and decreased in a weightrelated fashion in children, with minimal changes observed in adults. This pattern was consistent whether phenobarbitone was administered alone or coadministered with carbamazepine or valproic acid. When phenobarbitone was coadministered with carbamazepine or valproic acid, phenobarbitone CL decreased compared with that in monotherapy. Its magnitudes in the presence of carbamazepine are maximal in early childhood (about 54%) and decreased in a weight-related fashion in older children, with minimal changes observed in adults. Concomitant administration of phenobarbitone and valproic acid resulted in a 35.8% decrease of phenobarbitone CL.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume54
Issue number1
DOIs
Publication statusPublished - May 7 1998

Fingerprint

Phenobarbital
Drug Interactions
Carbamazepine
Valproic Acid
Pharmaceutical Preparations
Population
Carbon Monoxide
Anticonvulsants
Body Weight
Pediatrics
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. / Yukawa, E.; To, H.; Ohdo, Shigehiro; Higuchi, S.; Aoyama, T.

In: European Journal of Clinical Pharmacology, Vol. 54, No. 1, 07.05.1998, p. 69-74.

Research output: Contribution to journalArticle

@article{bc17e530e6f64cae944a4bdac1fa882f,
title = "Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling",
abstract = "Objective: Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effects of drug interaction on phenobarbitone clearance values, using 648 serum levels gathered during the routine clinical care of 349 pediatric and adult epileptic patients (age range, 0.4-33.3 years). Patients received phenobarbitone as monotherapy or in combination with either of the antiepileptic drugs carbamazepine or valproic acid. Results: The final model describing phenobarbitone clearance was CL = 52.3·TBW-0.567. CO, where CL is clearance (ml· kg-1· h-1), TBW is total body weight (kg) and CO is a scaling factor for concomitant medication with a value of 1 for patients on phenobarbitone monotherapy, 46.4(-1/TBW) for those patients receiving concomitant carbamazepine and 0.642 for those patients receiving concomitant valproic acid. Phenobarbitone CL was highest in the very young and decreased in a weightrelated fashion in children, with minimal changes observed in adults. This pattern was consistent whether phenobarbitone was administered alone or coadministered with carbamazepine or valproic acid. When phenobarbitone was coadministered with carbamazepine or valproic acid, phenobarbitone CL decreased compared with that in monotherapy. Its magnitudes in the presence of carbamazepine are maximal in early childhood (about 54{\%}) and decreased in a weight-related fashion in older children, with minimal changes observed in adults. Concomitant administration of phenobarbitone and valproic acid resulted in a 35.8{\%} decrease of phenobarbitone CL.",
author = "E. Yukawa and H. To and Shigehiro Ohdo and S. Higuchi and T. Aoyama",
year = "1998",
month = "5",
day = "7",
doi = "10.1007/s002280050423",
language = "English",
volume = "54",
pages = "69--74",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling

AU - Yukawa, E.

AU - To, H.

AU - Ohdo, Shigehiro

AU - Higuchi, S.

AU - Aoyama, T.

PY - 1998/5/7

Y1 - 1998/5/7

N2 - Objective: Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effects of drug interaction on phenobarbitone clearance values, using 648 serum levels gathered during the routine clinical care of 349 pediatric and adult epileptic patients (age range, 0.4-33.3 years). Patients received phenobarbitone as monotherapy or in combination with either of the antiepileptic drugs carbamazepine or valproic acid. Results: The final model describing phenobarbitone clearance was CL = 52.3·TBW-0.567. CO, where CL is clearance (ml· kg-1· h-1), TBW is total body weight (kg) and CO is a scaling factor for concomitant medication with a value of 1 for patients on phenobarbitone monotherapy, 46.4(-1/TBW) for those patients receiving concomitant carbamazepine and 0.642 for those patients receiving concomitant valproic acid. Phenobarbitone CL was highest in the very young and decreased in a weightrelated fashion in children, with minimal changes observed in adults. This pattern was consistent whether phenobarbitone was administered alone or coadministered with carbamazepine or valproic acid. When phenobarbitone was coadministered with carbamazepine or valproic acid, phenobarbitone CL decreased compared with that in monotherapy. Its magnitudes in the presence of carbamazepine are maximal in early childhood (about 54%) and decreased in a weight-related fashion in older children, with minimal changes observed in adults. Concomitant administration of phenobarbitone and valproic acid resulted in a 35.8% decrease of phenobarbitone CL.

AB - Objective: Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effects of drug interaction on phenobarbitone clearance values, using 648 serum levels gathered during the routine clinical care of 349 pediatric and adult epileptic patients (age range, 0.4-33.3 years). Patients received phenobarbitone as monotherapy or in combination with either of the antiepileptic drugs carbamazepine or valproic acid. Results: The final model describing phenobarbitone clearance was CL = 52.3·TBW-0.567. CO, where CL is clearance (ml· kg-1· h-1), TBW is total body weight (kg) and CO is a scaling factor for concomitant medication with a value of 1 for patients on phenobarbitone monotherapy, 46.4(-1/TBW) for those patients receiving concomitant carbamazepine and 0.642 for those patients receiving concomitant valproic acid. Phenobarbitone CL was highest in the very young and decreased in a weightrelated fashion in children, with minimal changes observed in adults. This pattern was consistent whether phenobarbitone was administered alone or coadministered with carbamazepine or valproic acid. When phenobarbitone was coadministered with carbamazepine or valproic acid, phenobarbitone CL decreased compared with that in monotherapy. Its magnitudes in the presence of carbamazepine are maximal in early childhood (about 54%) and decreased in a weight-related fashion in older children, with minimal changes observed in adults. Concomitant administration of phenobarbitone and valproic acid resulted in a 35.8% decrease of phenobarbitone CL.

UR - http://www.scopus.com/inward/record.url?scp=0031979016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031979016&partnerID=8YFLogxK

U2 - 10.1007/s002280050423

DO - 10.1007/s002280050423

M3 - Article

C2 - 9591934

AN - SCOPUS:0031979016

VL - 54

SP - 69

EP - 74

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -